A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise

Phase 3

Active, not recruiting

• Conditions: Type 2 Diabetes
• Interventions: Drug: Placebo; Drug: Cagrilintide; Drug: Semaglutide

• Registration Number: NCT06323174
• Lead Sponsor: Novo Nordisk A/S

Brief Summary

This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body. Participants will get either CagriSema or "dummy" medicine. Which treatment participants get is decided by chance. For each participant, the study will last for about one year.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-03-15
• Study First Submitted QC: 2024-03-15
• Study Start: 2024-03-19
• Study First Posted: 2024-03-21
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-29
• Last Update Posted: 2025-05-30
• Primary Completion: 2025-10-03
• Study Completion: 2025-12-26

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 180

Inclusion Criteria

• Male or female
• Age 18 years or above at the time of signing the informed consent
• Diagnosed with type 2 diabetes >=30 days before screening
• HbA1c 7.0-9.5 percent (53-80 millimoles per mole [mmol/mol]) (both inclusive) as determined by central laboratory at screening
• Body mass index (BMI) >=23 kilograms per square meter (kg/m^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening

Exclusion Criteria

• Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method
• Renal impairment with estimated Glomerular Filtration Rate less than 30 milliliter per minute per 1.73 square meter (ml/min/1.73 m^2) as determined by central laboratory at screening
• Treatment with any medication for the indication of diabetes or obesity within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed
• History of use of any injectable therapy for diabetes or obesity. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed
• Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
CagriSema Dose 2	Semaglutide	Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 16-week dose escalation period until target dose (dose 2) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 24 weeks.
Placebo Dose 2	Placebo	Participants will receive once-weekly s.c injection of placebo matched to Cagrisema (cagrilintide and semaglutide) dose 2 for 40 weeks.
Cagrisema Dose 1	Semaglutide	Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 8-week dose escalation period until target dose (dose 1) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 32 weeks.
Placebo Dose 1	Placebo	Participants will receive once-weekly s.c injection of placebo matched to Cagrisema (cagrilintide and semaglutide) dose 1 for 40 weeks.
CagriSema Dose 2	Cagrilintide	Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 16-week dose escalation period until target dose (dose 2) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 24 weeks.
Cagrisema Dose 1	Cagrilintide	Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 8-week dose escalation period until target dose (dose 1) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 32 weeks.

Primary Outcome Measures

Name	Time	Method
Change in glycated haemoglobin (HbA1c)	From baseline (week 0) to end of treatment (week 40)	Measured as percentage (%)-points.

Secondary Outcome Measures

Name	Time	Method
Relative change in body weight	From baseline (week 0) to end of treatment (week 40)	Measured in %.
Number of participants who achieve greater than or equal to (>=) 10% body weight reduction	From baseline (week 0) to end of treatment (week 40)	Measured as count of participants.
Number of participants who achieve >=15% body weight reduction	From baseline (week 0) to end of treatment (week 40)	Measured as count of participants.
Number of participants who achieve HbA1c target values of less than (<) 7.0% (<53 millimoles per mole [mmol/mol])	At end of treatment (week 40)	Measured as count of participants.
Number of participants who achieve HbA1c target values of less than or equal to (<=) 6.5% (<= 48 mmol/mol)	At end of treatment (week 40)	Measured as count of participants.
Change in Fasting Plasma Glucose (FPG)	From baseline (week 0) to end of treatment (week 40)	Measured in millimoles per liter (mmol/L).
Number of participants who achieve >=5% body weight reduction	From baseline (week 0) to end of treatment (week 40)	Measured as count of participants.
Change in waist circumference	From baseline (week 0) to end of treatment (week 40)	Measured in centimeters (cm).
Change in systolic blood pressure (SBP)	From baseline (week 0) to end of treatment (week 40)	Measured in millimeters of mercury (mmHg).
Change in diastolic blood pressure (DBP)	From baseline (week 0) to end of treatment (week 40)	Measured in mmHg.
Number of participants who achieve >=20% body weight reduction	From baseline (week 0) to end of treatment (week 40)	Measured as count of participants.
Ratio to baseline in high sensitivity C-reactive protein (hsCRP)	From baseline (week 0) to end of treatment (week 40)	Measured as ratio.
Ratio to baseline in lipids: Total cholesterol	From baseline (week 0) to end of treatment (week 40)	Measured as ratio.
Ratio to baseline in lipids: Low-density lipoprotein (LDL) cholesterol	From baseline (week 0) to end of treatment (week 40)	Measured as ratio.
Ratio to baseline in lipids: High-density lipoprotein (HDL) cholesterol	From baseline (week 0) to end of treatment (week 40)	Measured as ratio.
Ratio to baseline in lipids: Triglycerides	From baseline (week 0) to end of treatment (week 40)	Measured as ratio.
Ratio to baseline in lipids: Non-HDL cholesterol	From baseline (week 0) to end of treatment (week 40)	Measured as ratio.
Number of participants who achieve type 2 diabetes (T2D) remission (HbA1c <6.5% and no antidiabetic medication)	At end of study (week 52)	Measured as count of participants.
Ratio to baseline in oral glucose tolerance test (OGTT) based oral glucose disposition index (DIo)	From baseline (week 0) to end of treatment (week 40)	Measured as ratio.
Change in experienced level of energy as measured by the SF-36v2 Health Survey Acute (SF-36v2) Vitality score	From baseline (week 0) to end of treatment (week 40)	Measured as score points. SF-36v2 Acute measures Health-Related Quality of Life (HRQoL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10.; Higher scores indicate better functional health and well-being. The vitality score range is from 25.6 to 69.1.
Ratio to baseline in lipids: Very low-density lipoprotein (VLDL) cholesterol	From baseline (week 0) to end of treatment (week 40)	Measured as ratio.
Ratio to baseline in lipids: Free fatty acids	From baseline (week 0) to end of treatment (week 40)	Measured as ratio.
Change in SF-36v2 score: Physical Component Summary score	From baseline (week 0) to end of treatment (week 40)	Measured as score points. SF-36v2 Acute measures HRQoL. The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The score range for physical component summary is 6.1 to 79.7.
Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) score	From baseline (week 0) to end of treatment (week 40)	Measured as score points. DTSQs measures treatment satisfaction and diabetes-specific quality of life. The measure consists of 8 items yielding 1 global score and 2 single item scores. Higher scores on the global score indicate greater satisfaction with treatment. Lower scores on the single-item scores indicate BG levels closer to the ideal, while higher scores indicate problems. Single-item scores (score range): Perceived frequency of hyperglycaemia (0-6), Perceived frequency of hypoglycaemia (0-6). Global score (score range): Total Treatment Satisfaction (0-36).
Change in leptin	From baseline (week 0) to end of treatment (week 40)	Measured in nanograms per milliliter (ng/mL).
Number of Treatment Emergent Adverse Events (TEAEs)	From baseline (week 0) to end of treatment +7 weeks (week 47)	Measured as count of events.
Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold	From baseline (week 0) to end of treatment + 7 weeks (week 47)	Measured as count of episodes.
Change in SF-36v2 score: Mental Component Summary score	From baseline (week 0) to end of treatment (week 40)	Measured as score points. SF-36v2 Acute measures HRQoL. The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The score range for mental component summary score is -3.8 to 78.7.
Change in soluble leptin receptor	From baseline (week 0) to end of treatment (week 40)	Measured in ng/mL.
Number of clinically significant hypoglycaemic episodes (level 2) (<3.0 mmol (54 milligrams per deciliter [mg/dL]), confirmed by blood glucose (BG) meter	From baseline (week 0) to end of treatment +7 weeks (week 47)	Measured as count of episodes.

Trial Locations

Locations (49)

Arcturus HC PLC Troy Med Res; 🇺🇸 Troy, Michigan, United States

Nat Res Inst Huntington Park; 🇺🇸 Huntington Park, California, United States

Valley Clinical Trials, Inc.; 🇺🇸 Northridge, California, United States

Southern California Dermatology; 🇺🇸 Santa Ana, California, United States

Encore Medical Research LLC; 🇺🇸 Hollywood, Florida, United States

Headlands Research Orlando; 🇺🇸 Orlando, Florida, United States

Encore Medical Research of Weston; 🇺🇸 Weston, Florida, United States

Alliance for Multispec Res; 🇺🇸 Newton, Kansas, United States

Brigham & Women's Hospital; 🇺🇸 Boston, Massachusetts, United States

Southgate Medical Group, LLP; 🇺🇸 West Seneca, New York, United States

Scroll for more (39 remaining)